with Covid-19, even in patients with SARS-CoV-2 infection who are not critically ill. Our results indicate that SARS-CoV-2 has an organotropism beyond the respiratory tract, including the kidneys, liver, heart, and brain, and we speculate that organotropism influences the course of Covid-19 disease and, possibly, aggravates preexisting conditions.

Victor G. Puelles, M.D., Ph.D.
Marc Lütgehetmann, M.D.
Tobias B. Huber, M.D.
University Medical Center Hamburg–Eppendorf
Hamburg, Germany
t.huber@uke.de

and Others
Drs. Puelles, Lütgehetmann, Lindenmeyer, and Sperhake contributed equally to this letter.

A complete list of authors is available with the full text of this letter at NEJM.org.

Supported by grants (CRC/1192, to Dr. Puelles; CRC/841, to Dr. Lütgehetmann; and CRC/1192, HU 1016/8-2, HU 1016/11-1, and HU 1016/12-1, to Dr. Huber) from the German Research Foundation and grants (eMed Consortia Fibromap, to Dr. Puelles; and STOP-FSGS-01GM1518C, to Dr. Huber) from the Federal Ministry of Education and Research.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on May 13, 2020, at NEJM.org.


DOI: 10.1056/NEJMc2011400

---

Transmission of SARS-CoV-2 in Domestic Cats

TO THE EDITOR: Reports of human-to-feline transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and of limited airborne transmission among cats prompted us to evaluate nasal shedding of SARS-CoV-2 from inoculated cats and the subsequent transmission of the virus by direct contact between virus-inoculated cats and cats with no previous infection with the virus. Three domestic cats were inoculated with SARS-CoV-2 on day 0. One day after inoculation, a cat with no previous SARS-CoV-2 infection was cohoused with each of the inoculated cats to assess whether transmission of the virus by direct contact would occur between the cats in each of the three pairs (Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Nasal and rectal swab specimens were obtained daily and immediately assessed for infectious virus on VeroE6/TMPRSS2 cells.

On day 1, we detected virus from two of the inoculated cats. By day 3, virus was detectable in all three inoculated cats, with continued detection of virus until day 5 in all cats and until day 6 in two of the three cats (Fig. 1).

The cats with no previous infection were cohoused with the inoculated cats on day 1. Two days later (day 3), one of the cats with no previous infection had infectious virus detected in a nasal swab specimen, and 5 days later, virus was detected in all three cats that were cohoused with the inoculated cats (Fig. 1). Virus titers in the cats that were cohoused with the inoculated cats peaked at 4.5 log10 plaque-forming units per milliliter, and virus shedding lasted 4 to 5 days (Fig. 1). No virus was detected in any of the rectal swabs tested. Although there have been reports of symptomatic infected cats, none of the cats in our study showed any symptoms, including abnormal body temperature, substantial weight loss (Fig. S1), or conjunctivitis. All the animals had IgG antibody titers between 1:5120 and 1:20,480 on day 24 after the initial inoculation.

With reports of transmission of SARS-CoV-2 from humans to domestic cats and to tigers and lions at the Bronx Zoo, coupled with our data showing the ease of transmission between domestic cats, there is a public health need to recognize and further investigate the potential chain of human–cat–human transmission. This is of particular importance given the potential for SARS-CoV-2 transmission between family members in households with cats while living under “shelter-in-place” orders. In 2016, an H7N2 influenza outbreak in New York City cat shelters highlighted the public health implications of
Correspondence

The New England Journal of Medicine

August 6, 2020

Cat-to-human transmission to workers in animal shelters. Moreover, cats may be a silent intermediate host of SARS-CoV-2, because infected cats may not show any appreciable symptoms that might be recognized by their owners. The Centers for Disease Control and Prevention has issued guidelines for pet owners regarding SARS-CoV-2 (www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/animals.html). Given the need to stop the coronavirus disease 2019 pandemic through various mechanisms, including breaking transmission chains, a better understanding of the role cats may play in the transmission of SARS-CoV-2 to humans is needed.

Peter J. Halfmann, Ph.D.
Masato Hatta, D.V.M., Ph.D.
Shiho Chiba, Ph.D.
Tadashi Maemura, D.V.M., Ph.D.
Shufang Fan, Ph.D.
University of Wisconsin
Madison, WI

Makoto Takeda, M.D., Ph.D.
National Institute of Infectious Diseases
Tokyo, Japan

Figure 1. Virus Titers from Nasal Swab Specimens.
Three inoculated cats were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on day 0. Three cats with no previous SARS-CoV-2 infection (direct contact) were cohoused in pairs (pairs 1, 2, and 3) with the inoculated cats on day 1. Nasal and rectal swab specimens were obtained on days 1 through 10. PFU denotes plaque-forming units.
Five-Year Outcomes with Transcatheter Aortic-Valve Replacement

TO THE EDITOR: The key message of the report by Makkar et al.1 and the editorial by Van Belle2 (Feb. 27 issue) on the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A trial is the effectiveness of transcatheter aortic-valve replacement (TAVR) in terms of death from any cause or disabling stroke at 5 years. Nonetheless, on critical appraisal, other important results are noted. The landmark analysis of events occurring between 2 and 5 years after the procedure (Fig. S4 in the Supplementary Appendix of the article, available at NEJM.org) shows that TAVR was associated with a higher risk of death or disabling stroke after 2 years than was surgical aortic-valve replacement, with a hazard that was 27% higher. Moreover, the intersection of the time-to-event curves (Fig. 1 of the article) and the wide differences between the hazard ratio at 0 to 2 years (0.89; 95% confidence interval [CI], 0.73 to 1.09) and that at 2 to 5 years (1.27; 95% CI, 1.06 to 1.53) suggest that the hazards were not constant over time. Therefore, the reported 5-year hazard ratio is not an accurate reflection of the findings, which require landmark analysis or time-varying modeling.3,4 The key message of the trial is also overshadowed by the disadvantage of TAVR in terms of reoperations and rehospitalization, which underscores concerns about the durability of TAVR devices. In summary, the 5-year results from the PARTNER 2 cohort A trial are not a swan song for surgery.

Fabio Barili, M.D., Ph.D.
S. Croce Hospital
Cuneo, Italy
fabarili@libero.it

Nicholas Freemantle, M.D.
University College London
London, United Kingdom

Alessandro Parolari, M.D., Ph.D.
IRCCS Policlinico S. Donato
Milan, Italy

Dr. Barili reports receiving fees from Abbott Medical for serving on an independent clinical event committee for a trial of the Trifecta valve; and Dr. Freemantle, receiving grants from the European Association for Cardio-Thoracic Surgery. No other potential conflict of interest relevant to this letter was reported.


DOI: 10.1056/NEJMc2018853

1. 2 Cats in NY become the first US pets to test positive for virus. AP News. April 22, 2020 (https://apnews.com/37328ab8db093bb8346e26e1840b48af8).

DOI: 10.1056/NEJMc2013400